LR Health & Beauty Records Strong Sales Growth of 7.2%
LR Health & Beauty – the leading digital social commerce company in Europe – has published its quarterly report for Q3 2024 and was able to announce a confirmation of the growth trend. The company, which specializes in nutritional supplements and cosmetic products, increased its sales significantly by 7.2% to EUR 69.4 million in the third quarter. The high demand for the new decorative cosmetics line LR ZEITGARD Signature and the large influx of new sales partners thanks to the realignment of the career plan were the primary contributors to this result.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204411818/en/
The company headquarters of LR Health & Beauty in Ahlen, Germany. (Photo: Business Wire)
Launch of decorative cosmetics line supports growth trend
In October, LR Health & Beauty expanded its product range to include the make-up line LR ZEITGARD Signature, whose launch has gone down as one of the most successful product launches in the company’s history. This represents a seamless continuation of the successful market launches of the recent past.
It was clear to CEO and Spokesman of the Management Board, Dr. Andreas Laabs, that the new product solution would be very well received: “In recent years, we have increasingly noticed that our partners’ desire for a first-class make-up line has grown. With LR ZEITGARD Signature, we are now responding to this need.” The range, which consists of a total of 19 high-quality products, delivers an impressive performance to sales partners and customers with its combination of nourishing textures and innovative technologies.
Realignment of the career plan ensures an influx of sales partners
Furthermore, the significant increase in new sales partners and the successful, ongoing development of existing sales careers are contributing to the successful growth of the company based in the town of Ahlen. This development is due to the completed realignment of the career plan for sales partners. On the one hand, this offers the LR partnership greater security in building up its business and, on the other, creates more attractive incentives for the further development of its own independence.
LR Health & Beauty prepares for future growth
With the new LR ZEITGARD Signature brand and the realignment of the career plan, the company is setting an important course for sustainable, profitable development in the future. LR is also preparing for future growth with the new logistics center at the company’s Ahlen site, which was put into operation in October 2024. A state-of-the-art warehousing system ensures efficiency gains and improves scaling options. “This year, we have launched important initiatives that will take full effect in the coming year. Against this backdrop, we are well positioned to enjoy an even more successful year,” reports Andreas Laabs.
The report for the third quarter of 2024 is available on the company’s website at https://ir.lrworld.com/
LR Group
Following the motto "More quality for your life" the LR Group with headquarters in Ahlen/Westphalia successfully produces and markets various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive social commerce company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool "LR neo" offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
LR has been firmly established on the market since 1985 as a "people business" company that focuses on people and personal advice. In times of changing working environments, the business model particularly appeals to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of Aloe Vera has been one of the core competencies of LR for more than 20 years. Only the valuable inside of the leaf is used for the products. In Ahlen, the company has established one of the most modern Aloe Vera production sites for Aloe Vera Drinking Gels in Europe.
In autumn 2009, LR founded the LR Global Kids Fund e.V., which supports deprived children and their families in many countries around the world efficiently and unbureaucratically in cooperation with local institutions. For further information on our commitment to sustainability, please read our sustainability report.
LR currently has around 1,200 employees and hundreds of thousands of registered community members.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204411818/en/
Contacts
PR Contact:
LR Global Holding
Almut Kellermeyer
Head of PR / Public Affairs
Kruppstraße 55
59227 Ahlen
Tel.: 02382 7060-106
E-mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.lrworld.com
%2F&esheet=54161659&newsitemid=20241204411818&lan=en-US&anchor=https%3A%2F%2Fir.
lrworld.com%2F&index=3&md5=61bcc8fda7a9619e345a97a04bbce5ab
IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 09:00:00 CET | Press Release
With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global international showcase for food innovation, allowing brands and companies to ex
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press Release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press Release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press Release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom